Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Rosneft and Indian Oil have agreed to increase oil supplies to India

3/29/23 ROSN

Kamaz plans to open a production and service center in Kyrgyzstan

3/29/23 KMAZ

Yakutskenergo reported for 2022 according to RAS

3/29/23 YKEN

Etalon Group's profits quadrupled in 2022

3/29/23 ETLN

Lenta reported for 2022 according to IFRS

3/29/23 LENT

VTB raised ₽149 billion as part of the first stage of additional capitalization

3/29/23 VTBR

Lenenergo reported for 2022 according to RAS

3/29/23 LSNG

Micron reported 6 months of fiscal year 2023

3/29/23 MU

The Micron Technology announced a quarterly dividend

3/28/23 MU

Segezha Group plans to produce fertilizers at Segezha PPM

3/28/23 SGZH